As regulatorsdemand more capital for riskier activities and companies and fund managers gravitate toward the bigger, more solid banks, some players are dropping out.
To Krumholz, this is part of a larger tapestry of unexpected clinical trial results that should make doctors, patients and regulatorsdemand more hard information about whether drugs reduce symptoms or prevent problems like heart attacks and deaths.